

Ref: FOI/GS/ID 4829

Please reply to:
 FOI Administrator
 Trust Management
 Maidstone Hospital
 Hermitage Lane
 Maidstone
 Kent
 ME16 9QQ
 Email: mtw-tr.foiadmin@nhs.net

16 August 2018

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Prostate cancer and Hepatocellular Carcinoma.

You asked:

Within your trust how many patients with advanced Prostate cancer have been treated in the past 12 months with the following treatments?

Abiraterone (Zytiga)

Cabazitaxel (Jevtana)

Docetaxel (Taxotere)

Enzalutamide (Xtandi)

Radium-223 (Xofigo)

How many patients being treated with Abiraterone or Enzalutamide and have been on this treatment for more than 1 year?

Within your trust how many patients with Hepatocellular Carcinoma (HCC) have been treated in the past 12 months with the following treatments?

Patients who have undergone Transarterial chemoembolization (TACE)

Bevacizumab (Avastin)

Everolimus (Afinitor)

Lapatinib (Tyverb)

Sorafenib (Nexavar)

Sunitinib (Sutent)

Stivarga (Regorafenib)

Others

Trust response:

Prostate

		More than a year
Abiraterone (Zytiga)	15	5

Cabazitaxel (Jevtana)	1	
Docetaxel (Taxotere)	9	
Enzalutamide (Xtandi)	6	1
Radium-223 (Xofigo)	44	

HCC

Bevacizumab (Avastin)	
Everolimus (Afinitor)	
Lapatinib (Tyverb)	
Sorafenib (Nexavar)	
Sunitinib (Sutent)	1
Stivarga (Regorafenib)	